Drug Price Trends for NDC 57237-0097

Average Pharmacy Cost for 57237-0097

Drug Name	NDC	Price/Unit ($)	Unit	Date
CEFADROXIL 250 MG/5 ML SUSP	57237-0097-01	0.17355	ML	2024-12-18
CEFADROXIL 250 MG/5 ML SUSP	57237-0097-01	0.17415	ML	2024-11-20
CEFADROXIL 250 MG/5 ML SUSP	57237-0097-01	0.17226	ML	2024-10-23

Best Wholesale Price for NDC 57237-0097

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

57237-0097 Market Analysis and Financial Projection

Market Analysis and Price Projections for Ondansetron (NDC: 57237-077)

Introduction

Ondansetron, a widely used antiemetic medication, is crucial in managing nausea and vomiting associated with chemotherapy, radiation therapy, and surgery. Here, we will delve into the market analysis and price projections for ondansetron, specifically focusing on the NDC code 57237-077, which corresponds to ondansetron orally disintegrating tablets.

Market Overview

The pharmaceutical market, particularly the segment involving antiemetic drugs, is influenced by several factors including technological advancements, regulatory changes, and patient needs.

Biopharma and Biotech Market Growth

The biopharma and biotech industries are experiencing significant growth, with the biopharma market estimated to be over $400 billion in 2024 and projected to grow at a CAGR of 7.56% between 2024 and 2029[3]. This growth is driven by innovations in clinical trial designs, evolving regulatory landscapes, and a shift towards patient-centered care.

Ondansetron Market Analysis

Clinical Use and Demand

Ondansetron is a serotonin 5-HT3 receptor antagonist used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. Its widespread use in oncology and other therapeutic areas ensures a steady demand.

Competitive Landscape

The antiemetic market is competitive, with several brands and generics available. However, ondansetron remains a preferred choice due to its efficacy and safety profile. The presence of generic versions, such as those from Rising Pharma Holdings, Inc., contributes to the competitive pricing[1].

Price Projections

Current Pricing

As of January 1, 2023, the pricing for ondansetron orally disintegrating tablets can vary based on the NDC code and the packager. However, specific pricing details for NDC 57237-077 are not provided in the available sources. Generally, generic versions of ondansetron tend to be more affordable compared to brand-name counterparts.

Future Pricing Trends

Given the competitive nature of the market and the presence of generics, prices for ondansetron are likely to remain stable or see modest decreases. Here are some key factors influencing future pricing:

• Generic Competition: The availability of generic ondansetron from multiple manufacturers keeps prices competitive. As more generics enter the market, prices may decrease[1].
• Regulatory Environment: Changes in regulatory frameworks can impact pricing, but generally, they aim to promote competition and reduce costs[3].
• Market Dynamics: The overall pharmaceutical market trends, including the growth of biopharma and biotech, can influence pricing strategies. However, for established drugs like ondansetron, these trends may have a minimal direct impact on pricing.

Sales and Revenue Projections

While specific sales and revenue projections for NDC 57237-077 are not available, we can infer from broader market trends:

• Stable Demand: Ondansetron's consistent use in clinical settings ensures stable demand, which in turn supports steady sales.
• Generic Sales: Generic versions of ondansetron contribute significantly to the overall sales in the antiemetic market. As generics continue to gain market share, they are likely to drive sales volume rather than revenue growth.

Key Takeaways

• Market Stability: The market for ondansetron is expected to remain stable due to its established use and the presence of generics.
• Competitive Pricing: Prices are likely to be competitive due to the availability of multiple generic versions.
• Regulatory Influence: Regulatory changes may impact pricing but are generally aimed at promoting competition and reducing costs.
• Steady Demand: Ondansetron's demand is expected to remain steady due to its clinical utility.

FAQs

1. What is the primary use of ondansetron?

   • Ondansetron is primarily used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery.

2. Who is the packager for NDC 57237-077?

   • The packager for NDC 57237-077 is Rising Pharma Holdings, Inc.[1].

3. How does the presence of generics affect the pricing of ondansetron?

   • The presence of generics generally keeps prices competitive and may lead to modest decreases over time.

4. What are the key factors influencing the future pricing of ondansetron?

   • Key factors include generic competition, regulatory environment, and overall market dynamics.

5. Is ondansetron expected to see significant sales growth in the future?

   • While ondansetron is expected to maintain stable sales due to its established use, significant growth is unlikely due to the mature nature of the market.

Sources

1. DailyMed: Ondansetron Orally Disintegrating Tablets USP[1].
2. Missouri Specialty MAC: List of drugs with NDC codes and prices[2].
3. TFS CRO: Predictions for the Biopharma and Biotech Industries in 2025[3].